Results 231 to 240 of about 5,782 (258)
Some of the next articles are maybe not open access.
Bispecific antibodies engage T cells for antitumor immunotherapy
Expert Opinion on Biological Therapy, 2011Although considerable evidence supports the hypothesis that T cells play a critical role in the immune response against cancer, the ability to mount and sustain tumor-specific cellular responses in vivo remains a challenge. A strategy that harnesses the cytotoxic advantage of T cell therapy is the use of bispecific antibodies designed to engage and ...
Bryan D, Choi +5 more
openaire +2 more sources
Bispecific T-cell engager therapy for multiple myeloma
Best Practice & Research Clinical HaematologyWith upfront use of triplet- and quadruplet-based regimens coupled with autologous stem cell transplant (ASCT) and maintenance lenalidomide, a high proportion of multiple myeloma (MM) patients are achieving deep and durable responses. Yet, myeloma invariably relapses, with refractoriness to one or more drugs at first relapse.
Diana Cirstea +4 more
openaire +2 more sources
Myeloma evades T cell-engaging therapies
Nature Cancer, 2023Bruno Paiva, Jesús F. San-Miguel
openaire +2 more sources
Perils and Problems in Bispecific T-Cell Engager Antibodies
Current Drug Safety: Bispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity.
Bisht, Khushboo, Joshi Rajat, Kumar
openaire +2 more sources
CAR T cells engage in anticancer martial arts
Science Translational Medicine, 2017A clever redesign of the chimeric antigen receptor T cell concept turns a cancer-mediated immunosuppressive cytokine into a growth signal.
openaire +2 more sources
T cell receptor engagement can influence T cell motility
Transplantation Proceedings, 2001Marelli-Berg, F M +6 more
openaire +3 more sources
T cell engagers emerge as a compelling therapeutic modality
Journal of Experimental MedicineT cell engagers (TCEs) are antibody-based constructs designed to transiently reprogram cytotoxic T lymphocytes for target cell elimination by simultaneously binding the T cell receptor and a specific surface antigen on the target cell. Over the past 12 years, 10 TCEs were approved by the US Food and Drug Administration, and an additional two by the ...
P.A. Baeuerle +3 more
openaire +2 more sources
Tumor and T cell engagement by BiTE.
Discovery medicine, 2014Cancer immunotherapy attempts to exploit the capability of the immune system to attack malignant cells. Recent results suggest that clinical responses in patients point to this new mechanism as potentially beneficial in harnessing the immune system for combating established malignancies.
openaire +1 more source